TCRX
TScan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.39
+5.55%Margins
Gross margin
90.3%
EBITDA margin
-1575.6%
EBIT margin
-1695.1%
Net margin
-1655.4%
FCF margin
-1665.6%
-170.6%
Return on equity
-68.7%
Return on assets
-75.4%
Return on invested capital
0.04x
Asset turnover
-$116.3M
Cash from operations
$1.48
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026